SV

Street Verdict

Analyst Scorecard

LAURUSLABS · NSE

Laurus Labs Limited

₹2,294.6

-0.49% (-₹11.4)

Prev. close

₹2,306

Volume

8,79,357

Delivery %

51.9%

As of

20 Nov 2026

Price history

₹2,294.6+₹480.6 (+26.49%) · 3M
18 Aug 2026 → 20 Nov 2026
1,9002,0002,1002,2002,3002,40018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 6 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Dr. Satyanarayana Chava M.Sc., Ph.D.

Headquarters

Hyderabad

Employees

7,059

Key stats

Market cap

₹1.26 L Cr

P/E ratio (TTM)

93.8

Dividend yield

0.09%

EPS (TTM)

₹24.78

Beta (1Y · daily vs NIFTY 50)

0.73

Beta (5Y · monthly vs NIFTY 50)

0.97

Shares float

36.59 Cr

EPS · quarter ended Sept 2026

₹8.16

Upcoming earnings

22 Jan 2027

Financial Performance

01 · Financials

0 Cr2500 Cr5000 Cr7500 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0112₹-100%0%100%200%23 Mar 2001 Jul 2010 Nov 2008 Feb 2111 May 2117 Nov 2110 May 2203 Nov 2210 May 2302 Nov 2308 May 2406 Nov 2409 May 2531 Oct 2508 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-2000 Cr0 Cr2000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹4,813.51 Cr₹4,935.57 Cr₹6,040.55 Cr₹5,040.83 Cr₹5,553.96 Cr₹6,812.90 Cr
EBITDA
₹1,574.34 Cr₹1,437.73 Cr₹1,598.19 Cr₹803.84 Cr₹1,130.38 Cr₹1,832.66 Cr
₹983.82 Cr₹827.52 Cr₹790.11 Cr₹160.55 Cr₹358.32 Cr₹888.79 Cr
Diluted EPS
₹18.28₹15.35₹14.64₹2.97₹6.64₹16.45

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹5,751.00 Cr₹6,968.00 Cr₹7,660.00 Cr₹8,387.00 Cr₹9,336.00 Cr₹10,511.00 Cr
——₹2,015.09 Cr₹2,577.40 Cr₹2,763.73 Cr₹2,518.48 Cr
Stockholders' equity
₹2,597.00 Cr₹3,351.00 Cr₹4,038.00 Cr₹4,111.00 Cr₹4,473.00 Cr₹5,300.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹733.00 Cr₹911.00 Cr₹994.00 Cr₹666.00 Cr₹602.00 Cr₹1,624.00 Cr
Investing cash flow
₹-940.99 Cr₹-914.34 Cr₹-996.06 Cr₹-822.42 Cr₹-681.72 Cr₹-1,088.66 Cr
₹255.00 Cr₹30.00 Cr₹-27.00 Cr₹250.00 Cr₹39.00 Cr₹-525.00 Cr
Capital expenditure
₹-689.00 Cr₹-877.00 Cr₹-990.00 Cr₹-678.00 Cr₹-641.00 Cr₹-1,070.00 Cr
End cash position
₹48.46 Cr₹75.35 Cr₹45.67 Cr₹138.94 Cr₹99.54 Cr₹112.66 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21–Sep 22(4Q)Dec 22–Sep 23(4Q)Dec 23–Mar 24(2Q)Jun 24–Sep 24(2Q)Dec 24–Mar 25(2Q)Jun 25–Sep 25(2Q)Dec 25–Mar 26(2Q)Jun 26
Promoter27.30%27.27%27.20%27.19%27.18%27.62%27.59%27.49%27.47%
Public72.70%72.73%72.80%72.81%72.82%72.38%72.41%72.51%72.53%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

LAURUSLABS

Oyster Renewable Invests INR 372 Crore In 60.9 MW Wind-Solar Hybrid Project For Laurus Labs In Andhra Pradesh

SolarQuarter · 5 days ago

LAURUSLABS

Laurus Labs rises 5.32% in Tuesday's session

Global Banking & Finance Review · 5 days ago